Global Short Acting NRT Products Market Strategic Research Report

Scope of the Report

The global Short Acting NRT Products market size is predicted to grow from US$ 1,862 million in 2025 to US$ 2,676 million in 2032; it is expected to grow at a CAGR of 5.5% from 2026 to 2032.

Short-acting Nicotine Replacement Therapy (NRT) products are fast-acting treatments designed to help people manage sudden cravings and withdrawal symptoms during smoking cessation. These products, which include nicotine gum, lozenges, nasal sprays, and oral inhalers, deliver nicotine quickly into the bloodstream to provide immediate relief. Unlike long-acting NRTs like patches, short-acting forms can be used as needed throughout the day, offering more flexible and responsive support during the quitting process. They are often used in combination with other NRTs for more effective smoking cessation.

The growth of the Short-acting Nicotine Replacement Products market is primarily driven by the continued increase in smoking cessation demand worldwide and the rising need for products that can quickly relieve nicotine cravings and withdrawal symptoms. Short-acting products such as nicotine gums, lozenges, oral sprays, nasal sprays, and inhalers offer relatively rapid onset of action, flexible dosing, convenient on-demand use, and good portability, making them particularly suitable for managing sudden cravings during the quitting process. In addition, growing clinical acceptance of combination approaches that pair long-acting nicotine patches with short-acting nicotine replacement products is further expanding their use. Wider OTC availability, the rapid development of online pharmacies and e-commerce channels, and improved product accessibility are also supporting market adoption. Meanwhile, continued innovation in dosage strength, flavors, dosage forms, release speed, and overall user experience is broadening the addressable consumer base and application scenarios, thereby supporting steady growth of the global market.

This report presents a comprehensive overview of the global Short Acting NRT Products market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Nicotine Gum
• Nicotine Lozenges
• Nicotine Mouth Spray
• Nicotine Nasal Spray
• Others

Segment by Dose

• Low Dose
• Medium Dose
• High Dose

Segment by Route of Administration

• Oral NRT
• Nasal NRT

Segment by players, this report covers

• Kenvue
• Perrigo
• Dr. Reddy's Laboratories
• Haleon
• Philip Morris International
• Cipla
• Rusan Pharma
• Glenmark Pharmaceuticals
• Piramal Pharma
• Rubicon Consumer Healthcare
• Alkalon
• Sparsha Pharma
• TFI India Labs
• Nico Orgo Marketing
• Lucy Goods
• Blip
• AdhexPharma
• Jones

Segment by Application

• Online Sales
• Offline Sales

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Short Acting NRT Products market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Online Sales, Offline Sales evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact